Tradestie Institutional Equity Comparison Engine

FDMT vs CGON โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Momentum & Technical, Options & Structure while FDMT counters with relative strength in Growth & Margin. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FDMT N/M vs CGON N/M Fwd P/E
Growth & Margin Winner FDMT
Op Margin -222.7% vs -4293.5% ยท YoY +4505.6% vs -3.7%
Momentum & Technical Winner CGON
1Y +13.3% vs +125.0% ยท 52W Pos 47% vs 84%
Options & Structure Winner CGON
BREAKDOWN (10th %ile IV) vs CONSOLIDATION (85th %ile IV)
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
1M Return +41.93%
1Y Return +124.96%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FDMT +13.33% CGON +124.96% Spread: +111.63 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FDMT Revenue CGON Revenue FDMT Op. Margin CGON Op. Margin Margin Edge
FY2019 $10M N/A -729.4% N/A FDMT
FY2020 $10M N/A -424.0% N/A FDMT
FY2021 $20M N/A -395.5% N/A FDMT
FY2022 $0M N/A -3516.5% N/A FDMT
FY2023 $20M $0M -544.6% -27180.9% FDMT
FY2024 $0M $0M -507678.4% -10067.3% CGON
FY2025 $90M $0M -187.2% -4722.1% FDMT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FDMT (3) vs CGON (5)
Institutional Metric FDMT CGON Criterion Row Winner
Market Capitalization Scale $669.3M $6.3B Larger Scale CGON
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +4505.6% -3.7% Higher Growth FDMT
Operating Margin (TTM) Profitability -222.7% -4293.5% Higher Margin FDMT
Net Profit Margin Profitability -208.6% 0.0% Higher Margin CGON
Return on Equity (ROE) Capital Efficiency -56.7% -28.3% Higher ROE CGON
52-Week Range Position Momentum 47% ($7โ€“$17) 84% ($37โ€“$94) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 1.89ฮฒ ยท 90% Vol 0.75ฮฒ ยท 89% Vol Lower Realized Risk CGON
Unified Institutional Score Composite Signal 51.3 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FDMT vs CGON Buy Guide
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FDMT nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.